Selenium Nanoparticles Enhance NK Cell‐Mediated Tumoricidal Activity in Malignant Pleural Effusion via the TrxR1‐IL‐18RAP‐pSTAT3 Pathway
Source abstract
Abstract
Abstract Malignant pleural effusion (MPE) poses a significant challenge in local treatment, primarily attributed to its intricate tumor immune microenvironment. The immunosuppression of natural killer (NK) cells within the microenvironment, exacerbated by selenium (Se) deficiency, constitutes a pivotal treatment bottleneck. Building upon prior investigations, this study delves into the impact and mechanisms of functionalized lentinan selenium nanoparticles (LET‐SeNPs) on NK cells in MPE, presenting a novel local treatment strategy for lung adenocarcinoma with malignant pleural effusion (MPE‐LA). The synergistic application of LET‐SeNPs serves to replenish Se levels in MPE, modulate NK cells, augment their quantity, restore and enhance their functionality. Additionally, LET‐SeNPs facilitate NK cells activation through the TrxR1‐IL18RAP‐pSTAT3 pathway, resulting in effective lung cancer cell eradication and reduced pleural effusion production. Furthermore, pre‐stimulation of NK cells by LET‐SeNPs, combined with CAR‐NK cell therapy, harnesses the innate immune system, exhibiting a potent anti‐tumor effect. This research introduces a compelling strategy to advance the clinical implementation of targeted nanomaterials or lead compounds with explicit targets and mechanisms, thereby enhancing NK cell therapy for comprehensive diagnosis and treatment of MPE.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Immune Cell Function and Interaction · Selenium in Biological Systems · Cancer Immunotherapy and Biomarkers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Pulmonary and Critical Care Medicine Guangzhou Institute of Respiratory Health National Clinical Research Center for Respiratory Disease National Center for Respiratory Medicine State Key Laboratory of Respiratory Diseases The First Affiliated Hospital of Guangzhou Medical University Guangzhou 510120 China
College of Chemistry and Materials Science Jinan University Guangzhou 510632 China
Funding
National Natural Science Foundation of China · Natural Science Foundation of Guangdong Province
References (57)
Show source-provided references
1. 10.1093/clinchem/hvac00310.1093/clinchem/hvac003 ↗
2. 10.7150/thno.8508410.7150/thno.85084 ↗
3. 10.1200/JCO.2017.35.15_suppl.e2166010.1200/JCO.2017.35.15_suppl.e21660 ↗
4. 10.3322/caac.2170810.3322/caac.21708 ↗
5. 10.1200/JCO.2016.34.15_suppl.e2168410.1200/JCO.2016.34.15_suppl.e21684 ↗
6. 10.1016/j.jtho.2015.08.00310.1016/j.jtho.2015.08.003 ↗
7. Zheng Y. · Exploration. · 2022 · 2 · 9
8. 10.2174/157016381366616052414284610.2174/1570163813666160524142846 ↗
9. 10.1002/adfm.20230083310.1002/adfm.202300833 ↗
10. 10.34133/bmef.001610.34133/bmef.0016 ↗
11. 10.1038/s41467-021-27026-910.1038/s41467-021-27026-9 ↗
12. 10.1002/adfm.20220260310.1002/adfm.202202603 ↗
13. 10.1016/j.jtho.2015.08.00310.1016/j.jtho.2015.08.003 ↗
14. 10.1097/JTO.0b013e31826df20310.1097/JTO.0b013e31826df203 ↗
15. 10.1007/s00262-022-03365-410.1007/s00262-022-03365-4 ↗
16. 10.3390/molecules2901012010.3390/molecules29010120 ↗
17. 10.1186/s12951-023-01825-210.1186/s12951-023-01825-2 ↗
18. 10.1002/adfm.20230153810.1002/adfm.202301538 ↗
19. 10.1002/adhm.20210014910.1002/adhm.202100149 ↗
20. 10.1002/adfm.20221336410.1002/adfm.202213364 ↗
21. 10.1002/EXP.2021013410.1002/EXP.20210134 ↗
22. 10.1021/accountsmr.2c0014710.1021/accountsmr.2c00147 ↗
23. 10.1039/D2TB00581F10.1039/D2TB00581F ↗
24. 10.1039/C9BM00953A10.1039/C9BM00953A ↗
25. 10.1002/adfm.20230205410.1002/adfm.202302054 ↗
26. 10.1016/j.nantod.2020.10097510.1016/j.nantod.2020.100975 ↗
27. 10.1016/j.biomaterials.2019.11937710.1016/j.biomaterials.2019.119377 ↗
28. 10.1021/acsnano.9b1010310.1021/acsnano.9b10103 ↗
29. 10.1002/advs.20220251910.1002/advs.202202519 ↗
30. 10.1021/jacs.2c0880210.1021/jacs.2c08802 ↗
31. 10.1002/adma.20221217810.1002/adma.202212178 ↗
32. 10.1002/asia.20170122710.1002/asia.201701227 ↗
33. 10.1016/j.biomaterials.2019.11937710.1016/j.biomaterials.2019.119377 ↗
34. 10.1016/j.freeradbiomed.2022.07.02110.1016/j.freeradbiomed.2022.07.021 ↗
35. 10.1002/adfm.20221297010.1002/adfm.202212970 ↗
36. 10.1016/j.trecan.2023.08.00310.1016/j.trecan.2023.08.003 ↗
37. Handy D. E. · Biol. Med. · 2022 · 188 · 146
38. 10.1021/jacs.3c0217910.1021/jacs.3c02179 ↗
39. 10.1016/j.drup.2018.11.00110.1016/j.drup.2018.11.001 ↗
40. 10.1016/j.chempr.2022.03.01010.1016/j.chempr.2022.03.010 ↗
41. 10.1016/j.drup.2023.10103310.1016/j.drup.2023.101033 ↗
42. 10.1002/adfm.20231312210.1002/adfm.202313122 ↗
43. 10.1007/s12011-013-9786-510.1007/s12011-013-9786-5 ↗
44. 10.1111/1744-9987.1207110.1111/1744-9987.12071 ↗
45. 10.1016/j.cej.2022.13598410.1016/j.cej.2022.135984 ↗
46. 10.1164/rccm.201909-1819LE10.1164/rccm.201909-1819LE ↗
47. 10.1016/j.ajcnut.2022.11.00710.1016/j.ajcnut.2022.11.007 ↗
48. 10.1155/2018/243859810.1155/2018/2438598 ↗
49. 10.4161/onci.2363810.4161/onci.23638 ↗
50. 10.1002/adfm.20210306310.1002/adfm.202103063 ↗
51. 10.1038/s41571-020-0426-710.1038/s41571-020-0426-7 ↗
52. 10.1016/j.imlet.2012.04.01410.1016/j.imlet.2012.04.014 ↗
53. 10.1038/s41586-020-2422-610.1038/s41586-020-2422-6 ↗
54. 10.1016/j.semcancer.2006.10.00910.1016/j.semcancer.2006.10.009 ↗
55. 10.1182/blood-2013-05-49970710.1182/blood-2013-05-499707 ↗
56. 10.1016/j.drup.2020.10070210.1016/j.drup.2020.100702 ↗
57. 10.1016/j.biomaterials.2022.12137110.1016/j.biomaterials.2022.121371 ↗